The European Medicines Agency (EMA) recommends approving the vaccine from U.S. pharmaceutical giant Moderna. However, the formal decision will be made by the European Commission.
The vaccine is aimed at people over 50. According to the EMA, a study of 8,000 people showed that those who received the combined vaccine have antibody levels at least as high as those who received two separate injections.
